BackJade Biosciences Overview
Jade Biosciences, Inc.

Jade Biosciences Target Price

See Jade Biosciences's analyst price targets ($47) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$14.12

Average Target Price

$46.67230.5% upside

3 analysts in the last 4 months

High: $48 | Low: $45

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-11Jefferies$48239.9% upsideOpen
2026-08-10WedbushLaura Chico$47232.9% upsideOpen
2026-06-15UBS$45218.7% upsideOpen
2026-06-02Piper Sandler$55289.5% upsideOpen
2026-06-02GuggenheimVamil Divan$47232.9% upsideOpen
2026-05-11WedbushLaura Chico$34140.8% upsideOpen
2026-05-11Guggenheim$32126.6% upsideOpen
2026-04-27H.C. Wainwright$45218.7% upsideOpen
2026-03-06Stifel NicolausAlex Thompson$40183.3% upsideOpen
2026-01-07H.C. Wainwright$2577.1% upsideOpen
2025-10-09BTIG$2898.3% upsideOpen
2025-06-16GuggenheimVamil Divan$140.8% downsideOpen
2025-05-05Stifel NicolausAlex Thompson$1934.6% upsideOpen

Jade Biosciences (JBIO) FAQ

Jade Biosciences (JBIO) currently reports a target price of $47. Use the charts on this page to explore Jade Biosciences's target price history and peer comparisons.

Analysts' average 12-month price target for Jade Biosciences is $47, about 230.5% upside from the current share price of $14.12. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $47, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Jade Biosciences, and consider following JBIO for alerts when major investors trade the stock.

Jade Biosciences is classified in the Healthcare sector. On target price, it currently shows $47. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JBIO with unrelated industries.